HF
MBRX icon

HRT Financial’s Moleculin Biotech MBRX Stock Holding History

HRT Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31K Buy
+13,739
New +$45.5K ﹤0.01% 3523
2025
Q4 		– Sell
-4,608
Closed -$61K – 3674
2025
Q3 		$61K Buy
+4,608
New +$62.2K ﹤0.01% 2579
2023
Q2 		– Sell
-42
Closed -$15K – 2929
2023
Q1 		$15K Buy
+42
New +$18.4K ﹤0.01% 2211
2021
Q1 		– Sell
-5
Closed -$8K – 2960
2020
Q4 		$8K Buy
+5
New +$8.87K ﹤0.01% 1764
2019
Q4 		– Sell
-9
Closed -$22K – 1448
2019
Q3 		$22K Buy
+9
New +$23.3K ﹤0.01% 1335

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

HRT Financial's MBRX Position: Q1 2026 in Review

HRT Financial opened a new position in Moleculin Biotech (MBRX) in Q1 2026: 13,739 shares worth $31K. The stake represents ﹤0.01% of the portfolio and ranks #3523 among its holdings. This is a return to the name: HRT Financial previously reported a position in MBRX as recently as Q3 2025.

HRT Financial first reported a position in MBRX in Q3 2019 and has held it in 5 quarters since. The position peaked at $61K in Q3 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • HRT Financial held 13,739 shares of Moleculin Biotech worth $31K as of Q1 2026.
  • Moleculin Biotech was a new HRT Financial position in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3523 holding.
  • HRT Financial first reported a position in Moleculin Biotech in Q3 2019 and has held it in 5 quarters since.
  • HRT Financial's Moleculin Biotech position peaked at $61K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.